Tirzepatide vs Retatrutide: Research Profiles of the Dual and Triple Agonists
Incretin research moved fast: from single-receptor GLP-1 agonists to tirzepatide's dual agonism, and then to retatrutide's triple agonism. The two compounds are often lumped together, but their pharmacology — and the maturity of their evidence — differ in ways that matter for research design.
Receptor profiles
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptors | GIP + GLP-1 (dual) | GIP + GLP-1 + glucagon (triple) |
| Receptor balance | GIP-biased — full GIP agonist, weaker GLP-1 activity than native GLP-1 | Engineered imbalance: strongest at GIP, moderate glucagon, attenuated GLP-1 |
| Structure | 39 AA, C20 fatty-diacid, once-weekly kinetics | 39 AA, C20 fatty-diacid, once-weekly kinetics |
| Development status | Approved (type 2 diabetes, obesity) | Phase 3 (TRIUMPH program) — not approved anywhere |
What the published trials show
Tirzepatide carries a completed evidence base: the SURPASS program in diabetes and SURMOUNT in obesity, where SURMOUNT-1 reported mean weight reductions up to ~21% over 72 weeks at the highest dose — the result that established dual agonism as superior to GLP-1 alone for weight endpoints.
Retatrutide has phase 2 data, published in the New England Journal of Medicine in 2023: mean weight reduction of ~24% at 48 weeks at the top dose, with the trajectory not yet plateaued at study end — the strongest mid-stage result reported for any incretin compound. Phase 3 outcomes are pending; until they publish, its profile rests on a few hundred participants rather than tens of thousands.
The glucagon question
Retatrutide's third receptor is the scientifically interesting one. Glucagon agonism raises energy expenditure and drives hepatic fat oxidation — phase 2 sub-studies reported marked liver-fat reductions — but historically risked hyperglycemia, which the GIP/GLP-1 components appear to offset. Whether that balance holds at scale is precisely what phase 3 will answer, and why comparative receptor-signaling work in vitro remains active.
Choosing a research compound
- Benchmarking against an approved, fully characterized comparator → tirzepatide (GLP-2 T, 40mg vials).
- Studying glucagon-receptor contribution, energy expenditure, or the frontier triple-agonist pharmacology → retatrutide (GLP-3 Reta, 24mg vials).
- Single-receptor baseline for either → semaglutide (see its research overview).
Both compounds are large, lipidated peptides — handle like semaglutide: gentle reconstitution, refrigeration, no shaking. For research use only — not for human or veterinary use.